[Bio USA] Samsung Biologics steps up CDMO tech race

SAN DIEGO — Samsung Biologics is accelerating research and development efforts to strengthen its position in the contract development and manufacturing organization market by leveraging proprietary platforms, next-generation modalities and strategic technology investments. “Supporting core technology for contract development business is the most important task at (Samsung Biologics’ Bio R&D Center),” Jeong Hyeong-nam, chief of Samsung Biologics’ Bio R&D Center, said at press conference at the BI

By The Korea Herald